• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Secondary prevention of ischemic heart disease in primary care (PRESENCIAP)].初级保健中缺血性心脏病的二级预防(PRESENCIAP)
Aten Primaria. 2001 Jan;27(1):29-32. doi: 10.1016/S0212-6567(01)78769-0.
2
[Are the Framingham tables directly applicable to the Mediterranean population?].[弗雷明汉表格是否直接适用于地中海人群?]
Aten Primaria. 2002 Jun 15;30(1):29-31. doi: 10.1016/s0212-6567(02)78960-9.
3
[Prevention secondary to ischemic cardiopathy at the lipid level in primary care in Aragon. PRECIAR study 1].
Rev Esp Salud Publica. 2001 Mar-Apr;75(2):143-9.
4
Lipoprotein(a) as a risk factor associated with ischemic heart disease: Ouro Preto Study.脂蛋白(a)作为与缺血性心脏病相关的危险因素:欧鲁普雷图研究。
Atherosclerosis. 2007 Apr;191(2):454-9. doi: 10.1016/j.atherosclerosis.2006.04.031. Epub 2006 Jul 14.
5
Secondary prevention of ischaemic cardiac events.缺血性心脏事件的二级预防。
Clin Evid. 2003 Dec(10):188-230.
6
Primary care equals secondary prevention in ischemic heart disease.基层医疗等同于缺血性心脏病的二级预防。
J Gen Intern Med. 2011 Oct;26(10):1086-7. doi: 10.1007/s11606-011-1823-5.
7
Ischaemic heart disease and cholesterol. There's more to heart disease than cholesterol.缺血性心脏病与胆固醇。心脏病不仅仅与胆固醇有关。
BMJ. 1994 Apr 16;308(6935):1038, 1041.
8
Cholesterol, statins, and mortality.
Lancet. 2008 Apr 5;371(9619):1163. doi: 10.1016/S0140-6736(08)60518-8.
9
The association between processes, structures and outcomes of secondary prevention care among VA ischemic heart disease patients.退伍军人事务部缺血性心脏病患者二级预防护理的过程、结构与结果之间的关联。
BMC Cardiovasc Disord. 2006 Feb 9;6:6. doi: 10.1186/1471-2261-6-6.
10
[Evidence of the efficacy of hypocholesterolemic treatment in primary and secondary prevention of ischemic heart disease].
Med Clin (Barc). 2000;114 Suppl 2:1-10.

引用本文的文献

1
Impact of Implementing a Dyslipidemia Management Guideline on Cholesterol Control for Secondary Prevention of Ischemic Heart Disease in Primary Care.实施血脂异常管理指南对初级保健中缺血性心脏病二级预防的胆固醇控制的影响。
Int J Environ Res Public Health. 2020 Nov 19;17(22):8590. doi: 10.3390/ijerph17228590.
2
[Profile of the patient with inadequate follow-up and control of cardiovascular risk factors after suffering an acute myocardial infarction].[急性心肌梗死后心血管危险因素随访及控制不足患者的概况]
Aten Primaria. 2008 Oct;40(10):497-503. doi: 10.1157/13127230.
3
[The secondary prevention of ischaemic heart disease in Spain. A systematic review of observational studies].[西班牙缺血性心脏病的二级预防。观察性研究的系统评价]
Aten Primaria. 2006 Sep 30;38(5):250-7. doi: 10.1157/13092980.
4
[Lipid control in secondary prevention: multicenter observational study in primary care].二级预防中的血脂控制:基层医疗的多中心观察性研究
Aten Primaria. 2004 Jun 30;34(2):81-6. doi: 10.1016/s0212-6567(04)79464-0.
5
[Secondary prevention of ischaemic cardiopathy: are we doing it right?].[缺血性心脏病的二级预防:我们做得对吗?]
Aten Primaria. 2004 Jan;33(1):51-3. doi: 10.1016/s0212-6567(04)78880-0.
6
[Secondary prevention of ischaemic cardiopathy in a primary care center].[基层医疗中心缺血性心脏病的二级预防]
Aten Primaria. 2003 May 31;31(9):614-5. doi: 10.1016/s0212-6567(03)79227-0.

本文引用的文献

1
Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.β受体阻滞剂对心肌梗死后高危和低危患者死亡率的影响。
N Engl J Med. 1998 Aug 20;339(8):489-97. doi: 10.1056/NEJM199808203390801.
2
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.2型糖尿病患者以及有和没有既往心肌梗死的非糖尿病患者的冠心病死亡率。
N Engl J Med. 1998 Jul 23;339(4):229-34. doi: 10.1056/NEJM199807233390404.
3
Secondary prevention in coronary heart disease: baseline survey of provision in general practice.冠心病的二级预防:全科医疗服务提供情况的基线调查
BMJ. 1998 May 9;316(7142):1430-4. doi: 10.1136/bmj.316.7142.1430.
4
The secondary prevention of coronary artery disease.冠状动脉疾病的二级预防
Am J Med. 1997 Jun;102(6):572-81. doi: 10.1016/s0002-9343(97)00046-6.
5
Pharmacologic therapies after myocardial infarction.心肌梗死后的药物治疗。
Am J Med. 1996 Oct 8;101(4A):4A61S-69S; discussion 4A69S-70S. doi: 10.1016/s0002-9343(96)00322-1.
6
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.普伐他汀对胆固醇水平正常的心肌梗死患者冠状动脉事件的影响。胆固醇与再发事件试验研究人员。
N Engl J Med. 1996 Oct 3;335(14):1001-9. doi: 10.1056/NEJM199610033351401.
7
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.抗血小板治疗随机试验的协作综述——I:各类患者长期抗血小板治疗预防死亡、心肌梗死和中风。抗血小板试验协作组。
BMJ. 1994 Jan 8;308(6921):81-106.
8
Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction. SPRINT Study Group.首次心肌梗死后一年内复发梗死的预测因素及长期预后意义。SPRINT研究组。
Am J Cardiol. 1993 Oct 15;72(12):883-8. doi: 10.1016/0002-9149(93)91100-v.
9
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).4444例冠心病患者降胆固醇随机试验:斯堪的纳维亚辛伐他汀生存研究(4S)
Lancet. 1994 Nov 19;344(8934):1383-9.
10
Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.临床实践中冠心病的预防。欧洲心脏病学会、欧洲动脉粥样硬化学会和欧洲高血压学会特别工作组的建议。
Eur Heart J. 1994 Oct;15(10):1300-31. doi: 10.1093/oxfordjournals.eurheartj.a060388.

初级保健中缺血性心脏病的二级预防(PRESENCIAP)

[Secondary prevention of ischemic heart disease in primary care (PRESENCIAP)].

出版信息

Aten Primaria. 2001 Jan;27(1):29-32. doi: 10.1016/S0212-6567(01)78769-0.

DOI:10.1016/S0212-6567(01)78769-0
PMID:11218971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7681477/
Abstract

OBJECTIVES

To find the degree of recording and control of cardiovascular risk factors among patients with chronic ischaemic cardiopathy and the use of drug therapies of proven efficacy on these patients.

DESIGN

Descriptive cross-sectional study.

SETTING

Two teaching health districts in Girona (one urban and one urban-rural).

PARTICIPANTS

There was an exhaustive sampling of the histories of all patients diagnosed with chronic ischaemic cardiopathy (n = 183).

MEASUREMENTS AND MAIN RESULTS

50% of the patients did not smoke, 58% did not consume alcohol and 45% took physical exercise. For 25%, 30% and 38%, respectively, these activities had not been recorded over the previous year. In 17% of cases blood pressure had not been recorded in the previous year; 61% had diastolic pressures < 90 mmHg, and 40% had systolic pressure < 140 mmHg. Total cholesterol determination was lacking in 28% of cases. 22% of patients had LDL-cholesterol levels below 130 mg/dl. 50% of patients had anti-aggregate or anti-coagulation treatment and 22% received beta-blocker treatment.

CONCLUSIONS

There is deficient recording of cardiovascular risk factors in patients with chronic coronary ischaemia and low prescription of those drugs that reduce morbidity and mortality. An improvement plan is needed in order to achieve better monitoring of these patients.

摘要

目的

了解慢性缺血性心脏病患者心血管危险因素的记录与控制程度,以及对这些患者使用经证实有效的药物治疗情况。

设计

描述性横断面研究。

地点

赫罗纳的两个教学健康区(一个城市区和一个城乡结合区)。

参与者

对所有诊断为慢性缺血性心脏病的患者(n = 183)的病史进行了详尽抽样。

测量与主要结果

50%的患者不吸烟,58%的患者不饮酒,45%的患者进行体育锻炼。分别有25%、30%和38%的患者在过去一年中这些活动未被记录。在17%的病例中,上一年未记录血压;61%的患者舒张压<90 mmHg,40%的患者收缩压<140 mmHg。28%的病例未进行总胆固醇测定。22%的患者低密度脂蛋白胆固醇水平低于130 mg/dl。50%的患者接受抗聚集或抗凝治疗,22%的患者接受β受体阻滞剂治疗。

结论

慢性冠状动脉缺血患者心血管危险因素的记录不足,降低发病率和死亡率的药物处方率较低。需要制定一个改进计划,以便更好地监测这些患者。